Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 5/20 | 0.47 |
| ▸ | IGF1R | P08069 | 6/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6155280 | 0.89 | KLF10 (0.44) | BCHEIGF1RALOX15 | |
| SCHEMBL6154950 | 0.87 | KLF10 (0.45) | IGF1RALOX15 | |
| SCHEMBL6154891 | 0.84 | HMGCR (0.39) | BCHEIGF1RALOX15PPARAESR1 | |
| SCHEMBL6154895 | 0.84 | HMGCR (0.39) | BCHEIGF1RALOX15PPARAESR1 | |
| SCHEMBL6884197 | 0.83 | ALOX15 (0.63) | IGF1RALOX15 | |
| SCHEMBL6155935 | 0.82 | IGF1R (0.41) | BCHEIGF1RALOX15 | |
| SCHEMBL30379508 | 0.80 | BCHE (0.46) | BCHEIGF1RALOX15ACHEESR1 | |
| SCHEMBL28999119 | 0.80 | BCHE (0.46) | BCHEIGF1RALOX15ACHEESR1 | |
| SCHEMBL9768519 | 0.79 | PPARA (0.58) | BCHEIGF1RALOX15ACHEPPARA | |
| SCHEMBL6155863 | 0.78 | MMP2 (0.42) | BCHEIGF1RALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1282636-C | Vitamin D analogues | GALDERMA RES & DEV (FR) | 2006-11-01 | — | — | CN | disclosed |
| CN-1332711-A | Vitamin D analogues | GALDERMA RES & DEV (FR) | 2002-01-23 | — | — | CN | disclosed |